| Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial R Phillips, WY Shi, M Deek, N Radwan, SJ Lim, ES Antonarakis, SP Rowe, ... JAMA oncology 6 (5), 650-659, 2020 | 803 | 2020 |
| Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer Z Szabo, E Mena, SP Rowe, D Plyku, R Nidal, MA Eisenberger, ... Molecular imaging and biology 17, 565-574, 2015 | 490 | 2015 |
| PSMA-Based [18F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer SP Rowe, KJ Macura, E Mena, AL Blackford, R Nadal, ES Antonarakis, ... Molecular imaging and biology 18, 411-419, 2016 | 260 | 2016 |
| Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging S Sheikhbahaei, A Afshar-Oromieh, M Eiber, LB Solnes, MS Javadi, ... European journal of nuclear medicine and molecular imaging 44, 2117-2136, 2017 | 257 | 2017 |
| E-PSMA: the EANM standardized reporting guidelines v1. 0 for PSMA-PET F Ceci, DE Oprea-Lager, L Emmett, JA Adam, J Bomanji, J Czernin, ... European journal of nuclear medicine and molecular imaging 48, 1626-1638, 2021 | 235 | 2021 |
| Prediction of response to immune checkpoint inhibitor therapy using early-time-point 18F-FDG PET/CT imaging in patients with advanced melanoma SY Cho, EJ Lipson, HJ Im, SP Rowe, EM Gonzalez, A Blackford, ... Journal of Nuclear Medicine 58 (9), 1421-1428, 2017 | 235 | 2017 |
| 18F-DCFBC PET/CT for PSMA-based detection and characterization of primary prostate cancer SP Rowe, KL Gage, SF Faraj, KJ Macura, TC Cornish, ... Journal of Nuclear Medicine 56 (7), 1003-1010, 2015 | 232 | 2015 |
| A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer … KJ Pienta, MA Gorin, SP Rowe, PR Carroll, F Pouliot, S Probst, ... The Journal of urology 206 (1), 52-61, 2021 | 226 | 2021 |
| Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study MJ Morris, SP Rowe, MA Gorin, L Saperstein, F Pouliot, D Josephson, ... Clinical Cancer Research 27 (13), 3674-3682, 2021 | 222 | 2021 |
| Prostate-specific membrane antigen ligands for imaging and therapy M Eiber, WP Fendler, SP Rowe, J Calais, MS Hofman, T Maurer, ... Journal of Nuclear Medicine 58 (Supplement 2), 67S-76S, 2017 | 214 | 2017 |
| PSMA ligands for PET imaging of prostate cancer SM Schwarzenboeck, I Rauscher, C Bluemel, WP Fendler, SP Rowe, ... Journal of Nuclear Medicine 58 (10), 1545-1552, 2017 | 202 | 2017 |
| PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges SP Rowe, MA Gorin, ME Allaf, KJ Pienta, PT Tran, MG Pomper, AE Ross, ... Prostate cancer and prostatic diseases 19 (3), 223-230, 2016 | 172 | 2016 |
| Prostate-specific membrane antigen as a target for cancer imaging and therapy AP Kiess, SR Banerjee, RC Mease, SP Rowe, A Rao, CA Foss, Y Chen, ... The quarterly journal of nuclear medicine and molecular imaging: official …, 2015 | 171 | 2015 |
| Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT SP Rowe, MA Gorin, HJ Hammers, M Som Javadi, H Hawasli, Z Szabo, ... Annals of nuclear medicine 29, 877-882, 2015 | 169 | 2015 |
| 18F-labeled, PSMA-targeted radiotracers: leveraging the advantages of radiofluorination for prostate cancer molecular imaging RA Werner, T Derlin, C Lapa, S Sheikbahaei, T Higuchi, FL Giesel, S Behr, ... Theranostics 10 (1), 1, 2020 | 148 | 2020 |
| Prospective evaluation of 99mTc-sestamibi SPECT/CT for the diagnosis of renal oncocytomas and hybrid oncocytic/chromophobe tumors MA Gorin, SP Rowe, AS Baras, LB Solnes, MW Ball, PM Pierorazio, ... European urology 69 (3), 413-416, 2016 | 147 | 2016 |
| Proposal for a structured reporting system for prostate-specific membrane antigen–targeted PET imaging: PSMA-RADS version 1.0 SP Rowe, KJ Pienta, MG Pomper, MA Gorin Journal of Nuclear Medicine 59 (3), 479-485, 2018 | 145 | 2018 |
| Molecular imaging in oncology: Current impact and future directions SP Rowe, MG Pomper CA: a cancer journal for clinicians 72 (4), 333-352, 2022 | 138 | 2022 |
| Imaging of nonprostate cancers using PSMA-targeted radiotracers: rationale, current state of the field, and a call to arms RAS Fragomeni, T Amir, S Sheikhbahaei, SC Harvey, MS Javadi, ... Journal of Nuclear Medicine 59 (6), 871-877, 2018 | 137 | 2018 |
| Diagnostic value of 18F-FDG PET/CT versus MRI in the setting of antibody-specific autoimmune encephalitis LB Solnes, KM Jones, SP Rowe, P Pattanayak, A Nalluri, A Venkatesan, ... Journal of Nuclear Medicine 58 (8), 1307-1313, 2017 | 129 | 2017 |
